Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential

  title={Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential},
  author={Andrew C Naglich and E. Sherwood Brown and Bryon Adinoff},
  journal={The American Journal of Drug and Alcohol Abuse},
  pages={341 - 354}
ABSTRACT Background: Bupropion is a substituted cathinone compound widely used as a first line or add-on treatment for depression, smoking cessation, and more recently in combination with naltrexone for weight loss. As abuse of synthetic cathinone compounds has received more attention in recent years, concern about the misuse potential of bupropion has grown as well. Objectives: We review bupropion pharmacology and assessments of misuse potential including preclinical evidence, human studies… 
3 Citations
Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia)
There is limited evidence supporting the cost-effectiveness of buPropion to augment citalopram, and dominance of vortioxetine compared to bupropion, for major depressive disorder with inadequate response to initial therapy.


A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.
The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors.
Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.
Clinically, bupropion is used as a treatment for two indications, as an antidepressant, the indication for which it was developed, and as a tobacco use cessation agent and is being tested as a candidate treatment for psychostimulant drug abuse, attention-deficit hyperactivity disorder (ADHD) and obesity.
Intravenous Administration and Abuse of Bupropion: A Case Report and a Review of the Literature
Another case of intravenous administration of and dependence on buPropion in a 29-year-old woman with a history of polysubstance dependence is presented, who consumed an extremely high daily dose of about 2400 mg of bupropion together with a daily oral dose of 2400 to 3600 mg of pregabalin.
An 11-year review of bupropion insufflation exposures in adults reported to the California Poison Control System
The abuse of bupropion by crushing and insufflating through the nose is uncommon compared with that by oral buPropion exposures reported to the California Poison Control System and the incidence of seizures appear to be rare.
Investigating the actions of bupropion on dependence-related effects of nicotine in rats
The results obtained with bupropion in these animal models of dependence suggest this antidepressant may not directly interact with stimulus properties of nicotine; rather its clinical efficacy may be exposed in animal models that are based upon chronic exposure to nicotine and upon abstinence effects.
Bupropion “Abuse” Reported to US Poison Centers
Most bupropion abuse occurs in adolescents and young adults, andTachycardia and seizures are common indicating the potential for serious effects, and providers should be aware of risk of buPropion abuse.
Bupropion abuse resulting in hypomania in a geriatric amphetamine user: A case report.
The first case of bupropion abuse documented in an older adult is reported in a 79-year-old gentleman with a history of alcohol and amphetamine use disorders, resulting in hypertension and hypomanic symptoms, emphasizing the need to consider bupropions abuse potential when prescribing it to older adults with risk factors for substance abuse.
Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent.
It is proposed that bupropion may have stimulant effects amenable to abuse that vary with route of administration, and health care providers may wish to exercise additional caution when prescribing buPropion to unfamiliar patients.
Seizures induced by recreational abuse of bupropion tablets via nasal insufflation.
The case of a patient with a recent history of generalized tonic-clonic seizures whose etiology was initially a diagnostic mystery, who presented to the emergency department with a recurrence of the seizures after crushing and nasally insufflating oral bupropion tablets is reported.
Amphetamine, past and present – a pharmacological and clinical perspective
The review charts advances in pharmaceutical development from the introduction of once-daily formulations of amphetamine through to lisdexamfetamine, which is the first d-amphetamine prodrug approved for the management of ADHD in children, adolescents and adults.